BioCentury

2:29 AM GMT, Nov 6, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Company News

FDA posts pasireotide briefing documents

FDA reviewers said pasireotide from Novartis AG (NYSE:NVS; SIX:NOVN) is effective for treating Cushing's disease, but

Read the full 161 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.